http://jcps.bjmu.edu.cn

Journal of Chinese Pharmaceutical Sciences ›› 2015, Vol. 24 ›› Issue (11): 701-711.DOI: 10.5246/jcps.2015.11.090

• Review •     Next Articles

Advances of N-terminal modifications of GLP-1 and their applications for the treatment of type 2 diabetes

Xiaohui Bai1, Youhong Niu1, Decai Xiong1, Yanfen Wu1*, Yunsen Li2*   

  1. 1. State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing 100191, China
    2. Suzhou Pharmavan Cancer Research Center Co., Ltd, Suzhou 215123, China
  • Received:2015-05-18 Revised:2015-07-28 Online:2015-11-20 Published:2015-08-15
  • Contact: Tel.: 86-10-82801558, E-mail: wuyanfen@pku.edu.cn, yunsenli@suda.edu.cn
  • Supported by:
    Beijing Natural Science Foundation (Grant No. 7152085).

Abstract:

Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic hormone with excellent blood glucose-lowering activity, however, it is rapidly inactivated in the plasma mainly by dipeptidyl peptidase IV (DPP-IV). To overcome this problem, various N-terminal modifications of GLP-1 have been performed to prolong the in vivo biological activity,by improving the DPP-IV resistance while retaining receptor affinity and receptor activation. These studies have included modifications of His7, Ala8 or Glu9 at the N-terminus of GLP-1 and some other modifications. Among them, Ala8 substitutions with glycine (Gly8) and α-aminoisobutyric acid (Aib8) have been clinically applied in the development of diabetic therapy, such as Exenatide, Semaglutide, Albiglutide and Taspoglutide. In this review, we introduce N-terminal modifications of GLP-1 that have been reported, and discuss their potential and challenges for the treatment of type 2 diabetes.

Key words: GLP-1 analogues, DPP-IV, N-terminal modification, Type 2 diabetes

CLC Number: 

Supporting: